Vascular Endothelial Growth Factor-Targeted Therapy for the Treatment of Renal Cell Carcinoma
- 1 June 2011
- journal article
- review article
- Published by Springer Nature in Drugs
- Vol. 71 (9) , 1179-1191
- https://doi.org/10.2165/11591410-000000000-00000
Abstract
Vascular endothelial growth factor (VEGF)-targeted agents have rapidly been adopted into standard-of-care treatment for renal cell carcinoma (RCC). However, a substantial proportion of patients fail...This publication has 58 references indexed in Scilit:
- Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnnals of Oncology, 2010
- Myelosuppression and kinase selectivity of multikinase angiogenesis inhibitorsBritish Journal of Cancer, 2009
- Expression of multidrug resistance markers ABCB1 (MDR-1/P-gp) and ABCC1 (MRP-1) in renal cell carcinomaBMC Urology, 2009
- High‐dose interleukin‐2 for the treatment of metastatic renal cell carcinomaCancer, 2008
- Cardiotoxicity associated with tyrosine kinase inhibitor sunitinibPublished by Elsevier ,2007
- Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trialThe Lancet, 2007
- Targeting vasculature in urologic tumors: Mechanistic and therapeutic significanceJournal of Cellular Biochemistry, 2007
- Estimates of the cancer incidence and mortality in Europe in 2006Annals of Oncology, 2007
- Sorafenib in Advanced Clear-Cell Renal-Cell CarcinomaNew England Journal of Medicine, 2007
- Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinomaCancer, 2003